BACKGROUND/AIM: Prostate cancer patients represent a small minority of those presenting with cerebral metastases.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Knowledge about overall survival (OS) contributes to individualization of treatment concepts. In this study an OS score was created for patients receiving whole-brain irradiation (WBI) for cerebral metastases from prostate cancer.
PATIENTS AND METHODS: Of six variables, four were significantly associated with OS: performance status, time from diagnosis of prostate cancer to WBI, number of cerebral lesions, extracranial metastases.
RESULTS: Six-month OS rates of the four variables (in %, divided by 10) were added. The addition resulted in scores of 1 to 19 points. Six-month OS rates were 0% for < 15 points and 100% for ≥15 points (p< 0.001).
CONCLUSION: An OS score was generated specifically for patients with cerebral lesions from prostate cancer. For patients with < 15 points, a short WBI regimen (5x4 Gy) should be used, for patients with ≥15 points a longer regimen seems appropriate.
Bartscht T, Rades D. Are you the author?
Department of Medical Oncology and Hematology, University of Lübeck, Lübeck, Germany; Department of Radiation Oncology University of Lübeck, Lübeck, Germany.
Reference: Anticancer Res. 2014 Aug;34(8):4357-60.